In the Press COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis October 2022 Read More COUR Pharmaceuticals Announces $30M Financing Led by Alpha Wave Ventures September 2022 Read More COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model August 2022 Read More COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer March 2022 Read More
COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis October 2022 Read More
COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model August 2022 Read More
